BBOT to Participate in Upcoming Investor Healthcare Conferences
BridgeBio Oncology Therapeutics, Inc. (BBOT)
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in the upcoming months. Details of the company’s participation are as follows: Oppenheimer 36th Annual Healthcare Life Sciences ConferencePresentation: Wednesday, February 25, 2026, at 10:40 a.m. ET. Leerink Global Healthcare ConferencePresentation: Tuesday, March 10, 2026, at 10:00 a.m. ET. Live webcasts of the presentations will be accessible on the “Events” page of the BBOT website at https://investors.bbotx.com/news-events/events. Replays of the webcasts will be available for at least 90 days following the event. About BBOTBBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka maligna
Show less
Read more
Impact Snapshot
Event Time:
BBOT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBOT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBOT alerts
High impacting BridgeBio Oncology Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
BBOT
News
- BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- BridgeBio Oncology Therapeutics (NASDAQ:BBOT) was given a new $23.00 price target on by analysts at Stifel Nicolaus.MarketBeat
- Biotech investor Cormorant secures $150M for another SPAC deal [Yahoo! Finance]Yahoo! Finance
- Helix Acquisition prices $150M initial public offering [Seeking Alpha]Seeking Alpha
- BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is now covered by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>. They set a "sell (d+)" rating on the stock.MarketBeat
BBOT
Sec Filings
- 1/27/26 - Form 8-K
- 1/26/26 - Form 4
- 1/23/26 - Form 424B4
- BBOT's page on the SEC website